

## National Clinical Guideline

---

Diagnosis, staging and Treatment of Gestational Trophoblastic Disease

### Literature Search Strategies

# Diagnosis

## Question 1

<b>Clinical Question</b>																																																							
Should all women undergoing medical management of miscarriage have histopathology of products of conception to exclude trophoblastic disease?																																																							
<b>PICO</b>																																																							
Population/Problem	Women undergoing medical management of miscarriage																																																						
Intervention/Indicator or	Histopathology of products of conception																																																						
Comparator/Control	-																																																						
Outcome	To identify partial or complete molar pregnancy																																																						
<b>Is the question specific to any of the categories below?</b>																																																							
<b>GENDER</b>	<b>AGE GROUP</b>	<b>DATE OF PUBLICATION</b>																																																					
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																																					
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>																																																					
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>																																																					
	Adult (19 – 65 years) <input type="checkbox"/>																																																						
	Aged (> 65 years) <input type="checkbox"/>																																																						
<b>Question Type</b>																																																							
Therapy/Intervention <input type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input checked="" type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																																				
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																																					
<b>Search Strategy</b>																																																							
Primary Database(s) Searched	MEDLINE																																																						
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S15</td> <td>S9 OR S13</td> <td>Limiters - Date of Publication from: 20000101-20131231</td> <td>55</td> </tr> <tr> <td>S14</td> <td>S9 OR S13</td> <td></td> <td>121</td> </tr> <tr> <td>S13</td> <td>S11 OR S12</td> <td></td> <td>57</td> </tr> <tr> <td>S12</td> <td>S7 AND S10</td> <td></td> <td>44</td> </tr> <tr> <td>S11</td> <td>S5 AND S10</td> <td></td> <td>57</td> </tr> <tr> <td>S10</td> <td>TI "product* of conception" OR AB "product* of conception"</td> <td></td> <td>718</td> </tr> <tr> <td>S9</td> <td>S6 OR S8</td> <td></td> <td>74</td> </tr> <tr> <td>S8</td> <td>S2 AND S7</td> <td></td> <td>65</td> </tr> <tr> <td>S7</td> <td>(MH "Hydatidiform Mole+")</td> <td></td> <td>4,471</td> </tr> <tr> <td>S6</td> <td>S2 AND S5</td> <td></td> <td>74</td> </tr> <tr> <td>S5</td> <td>S3 OR S4</td> <td></td> <td>11,496</td> </tr> <tr> <td>S4</td> <td>(MH "Trophoblastic Neoplasms+")</td> <td></td> <td>11,496</td> </tr> </tbody> </table>			#	Query	Limiters/Expanders	Results	S15	S9 OR S13	Limiters - Date of Publication from: 20000101-20131231	55	S14	S9 OR S13		121	S13	S11 OR S12		57	S12	S7 AND S10		44	S11	S5 AND S10		57	S10	TI "product* of conception" OR AB "product* of conception"		718	S9	S6 OR S8		74	S8	S2 AND S7		65	S7	(MH "Hydatidiform Mole+")		4,471	S6	S2 AND S5		74	S5	S3 OR S4		11,496	S4	(MH "Trophoblastic Neoplasms+")		11,496
#	Query	Limiters/Expanders	Results																																																				
S15	S9 OR S13	Limiters - Date of Publication from: 20000101-20131231	55																																																				
S14	S9 OR S13		121																																																				
S13	S11 OR S12		57																																																				
S12	S7 AND S10		44																																																				
S11	S5 AND S10		57																																																				
S10	TI "product* of conception" OR AB "product* of conception"		718																																																				
S9	S6 OR S8		74																																																				
S8	S2 AND S7		65																																																				
S7	(MH "Hydatidiform Mole+")		4,471																																																				
S6	S2 AND S5		74																																																				
S5	S3 OR S4		11,496																																																				
S4	(MH "Trophoblastic Neoplasms+")		11,496																																																				

	S3	(MH "Gestational Trophoblastic Disease+")	10,193
	S2	(MH "Abortion, Habitual+/PA") OR (MH "Abortion, Spontaneous+/PA") OR (MH "Abortion, Incomplete/PA") OR (MH "Abortion, Missed/PA")	1,166
	S1	TI "product* of conception" OR AB "product* of conception"	718
Other/Secondary Resources Searched	UpToDate; Cochrane; RCOG; MD Consult; Trip Database		
Search Strategy: Other Resources			
Comments			
Date			

## Question 2

Clinical Question																	
For women with suspected molar pregnancy, what diagnostic tests should be done to accurately diagnose partial or complete molar pregnancy?																	
PICO																	
Population/Problem	Women with suspected molar pregnancy																
Intervention/Indicator or	Diagnostic tests																
Comparator/Control	-																
Outcome	Accurately diagnose partial/complete molar pregnancy - sensitivity and specificity																
Is the question specific to any of the categories below?																	
GENDER	AGE GROUP	DATE OF PUBLICATION															
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>															
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>															
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>															
	Adult (19 – 65 years) <input type="checkbox"/>																
	Aged (> 65 years) <input type="checkbox"/>																
Question Type																	
Therapy/Intervention <input type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input checked="" type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>														
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other: <input type="checkbox"/>															
Search Strategy																	
Primary Database(s) Searched	Medline																
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S3</td> <td>(MM "Gestational Trophoblastic Disease+/Dl")</td> <td>Limiters - Date of Publication from: 20070101-20131231; Clinical Queries: Diagnosis - High Sensitivity</td> <td>181</td> </tr> <tr> <td>S2</td> <td>(MM "Gestational Trophoblastic Disease+/Dl")</td> <td>Limiters - Date of Publication from: 20070101-20131231</td> <td>181</td> </tr> <tr> <td>S1</td> <td>(MM "Gestational Trophoblastic Disease+/Dl")</td> <td></td> <td>1,053</td> </tr> </tbody> </table>	#	Query	Limiters/Expanders	Results	S3	(MM "Gestational Trophoblastic Disease+/Dl")	Limiters - Date of Publication from: 20070101-20131231; Clinical Queries: Diagnosis - High Sensitivity	181	S2	(MM "Gestational Trophoblastic Disease+/Dl")	Limiters - Date of Publication from: 20070101-20131231	181	S1	(MM "Gestational Trophoblastic Disease+/Dl")		1,053
#	Query	Limiters/Expanders	Results														
S3	(MM "Gestational Trophoblastic Disease+/Dl")	Limiters - Date of Publication from: 20070101-20131231; Clinical Queries: Diagnosis - High Sensitivity	181														
S2	(MM "Gestational Trophoblastic Disease+/Dl")	Limiters - Date of Publication from: 20070101-20131231	181														
S1	(MM "Gestational Trophoblastic Disease+/Dl")		1,053														
Other/Secondary Resources Searched	Cochrane (Incl Medline); TRIP database; UpToDate; Ebsco Discovery federated search																
Search Strategy: Other Resources																	
Comments																	
Date																	

### Question 3

Clinical Question																																																											
For women where there is suspicion of partial or complete molar pregnancy who have an evacuation performed, in what time frame should the pathology report (post-evacuation) be available to the clinician?																																																											
PICO																																																											
Population/Problem	Women With Suspected Partial Or Complete Molar Pregnancy																																																										
Intervention/Indicator	Histopathological review																																																										
Comparator/Control	-																																																										
Outcome	Time to report to clinicians																																																										
Is the question specific to any of the categories below?																																																											
GENDER	AGE GROUP	DATE OF PUBLICATION																																																									
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																																									
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>																																																									
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>																																																									
	Adult (19 – 65 years) <input type="checkbox"/>																																																										
	Aged (> 65 years) <input type="checkbox"/>																																																										
Question Type																																																											
Therapy/Intervention <input type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input checked="" type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																																								
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																																									
Search Strategy																																																											
Primary Database(s) Searched	Medline																																																										
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S19</td> <td>S15 AND S18</td> <td></td> <td>1</td> </tr> <tr> <td>S18</td> <td>(MH "Delayed Diagnosis")</td> <td>Limiters - Date of Publication from: 20020101-20121231</td> <td>1,539</td> </tr> <tr> <td>S17</td> <td>S10 AND S15</td> <td>Limiters - Date of Publication from: 20020101-20121231</td> <td>13</td> </tr> <tr> <td>S16</td> <td>S10 AND S15</td> <td></td> <td>91</td> </tr> <tr> <td>S15</td> <td>(MM "Hydatidiform Mole+")</td> <td></td> <td>3,353</td> </tr> <tr> <td>S14</td> <td>TI Routine pre-evacuation ultrasound diagnosis of</td> <td></td> <td>1</td> </tr> <tr> <td>S13</td> <td>S10 AND S12</td> <td></td> <td>22</td> </tr> <tr> <td>S12</td> <td>(MM "Hydatidiform Mole+/DI/PA")</td> <td></td> <td>907</td> </tr> <tr> <td>S11</td> <td>S4 AND S10</td> <td></td> <td>3</td> </tr> <tr> <td>S10</td> <td>(MH "Time Factors")</td> <td></td> <td>954,789</td> </tr> <tr> <td>S9</td> <td>"time to treatment" AND (mole OR molar) AND *pathol*</td> <td></td> <td>0</td> </tr> <tr> <td>S8</td> <td>S4 AND S7</td> <td></td> <td>0</td> </tr> <tr> <td>S7</td> <td>"time to treatment"</td> <td></td> <td>2,099</td> </tr> </tbody> </table>			#	Query	Limiters/Expanders	Results	S19	S15 AND S18		1	S18	(MH "Delayed Diagnosis")	Limiters - Date of Publication from: 20020101-20121231	1,539	S17	S10 AND S15	Limiters - Date of Publication from: 20020101-20121231	13	S16	S10 AND S15		91	S15	(MM "Hydatidiform Mole+")		3,353	S14	TI Routine pre-evacuation ultrasound diagnosis of		1	S13	S10 AND S12		22	S12	(MM "Hydatidiform Mole+/DI/PA")		907	S11	S4 AND S10		3	S10	(MH "Time Factors")		954,789	S9	"time to treatment" AND (mole OR molar) AND *pathol*		0	S8	S4 AND S7		0	S7	"time to treatment"		2,099
#	Query	Limiters/Expanders	Results																																																								
S19	S15 AND S18		1																																																								
S18	(MH "Delayed Diagnosis")	Limiters - Date of Publication from: 20020101-20121231	1,539																																																								
S17	S10 AND S15	Limiters - Date of Publication from: 20020101-20121231	13																																																								
S16	S10 AND S15		91																																																								
S15	(MM "Hydatidiform Mole+")		3,353																																																								
S14	TI Routine pre-evacuation ultrasound diagnosis of		1																																																								
S13	S10 AND S12		22																																																								
S12	(MM "Hydatidiform Mole+/DI/PA")		907																																																								
S11	S4 AND S10		3																																																								
S10	(MH "Time Factors")		954,789																																																								
S9	"time to treatment" AND (mole OR molar) AND *pathol*		0																																																								
S8	S4 AND S7		0																																																								
S7	"time to treatment"		2,099																																																								

	S6	S4 AND S5		15
	S5	TX hour* OR day* OR week* OR time*	Limiters - Clinical Queries: Diagnosis - High Sensitivity	592,857
	S4	S1 OR S2	Limiters - Date of Publication from: 20020101-20131231	349
	S3	S1 OR S2		1,156
	S2	(MM "Gestational Trophoblastic Disease+/PA")		1,156
	S1	(MM "Hydatidiform Mole+/PA")		349
	Other/Secondary Resources Searched	Uptodate; Cochrane; Rcoq; Md Consult; Trip Database		
Search Strategy: Other Resources				
Comments				
Date				

## Question 4

Clinical Question																																																													
For women with gestational trophoblastic disease should management be centralised to a specialised centre(s) to ensure optimum outcome?																																																													
PICO																																																													
Population/Problem	Women with confirmed GTD																																																												
Intervention/Indicat	Registration and central advice																																																												
Comparator/Contr	-																																																												
Outcome	Optimum outcomes - early appropriate management - improved overall survival - protocol-driven systemic therapy administration																																																												
Is the question specific to any of the categories below?																																																													
GENDER	AGE GROUP	DATE OF PUBLICATION																																																											
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																																											
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>																																																											
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>																																																											
	Adult (19 – 65 years) <input type="checkbox"/>																																																												
	Aged (> 65 years) <input type="checkbox"/>																																																												
Question Type																																																													
Therapy/Intervention	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input checked="" type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																																										
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																																											
Search Strategy																																																													
Primary Database(s) S searched	Medline																																																												
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S14</td> <td>S1 AND S13</td> <td></td> <td>147</td> </tr> <tr> <td>S13</td> <td>(MH "Quality of Health Care+")</td> <td></td> <td>4,505,550</td> </tr> <tr> <td>S12</td> <td>S1 AND S11</td> <td></td> <td>0</td> </tr> <tr> <td>S11</td> <td>(MH "Oncology Service, Hospital/OG/ST/TD/EC")</td> <td></td> <td>523</td> </tr> <tr> <td>S10</td> <td>S1 AND S9</td> <td></td> <td>3</td> </tr> <tr> <td>S9</td> <td>(MH "Academic Medical Centers+")</td> <td></td> <td>65,856</td> </tr> <tr> <td>S8</td> <td>S3 OR S5 OR S7</td> <td></td> <td>49</td> </tr> <tr> <td>S7</td> <td>S1 AND S6</td> <td></td> <td>44</td> </tr> <tr> <td>S6</td> <td>(MH "Outcome Assessment (Health Care)+") OR (MH "Outcome and Process Assessment (Health Care)+")</td> <td></td> <td>631,762</td> </tr> <tr> <td>S5</td> <td>S1 AND S4</td> <td></td> <td>3</td> </tr> <tr> <td>S4</td> <td>(MH "Referral and Consultation+")</td> <td></td> <td>52,940</td> </tr> <tr> <td>S3</td> <td>S1 AND S2</td> <td></td> <td>5</td> </tr> <tr> <td>S2</td> <td>TX specialist OR AB specialist OR TI specialist</td> <td></td> <td>97,872</td> </tr> <tr> <td>S1</td> <td>(MM "Gestational Trophoblastic Disease")</td> <td>Limiters - Date of Publication from:</td> <td>257</td> </tr> </tbody> </table>	#	Query	Limiters/Expanders	Results	S14	S1 AND S13		147	S13	(MH "Quality of Health Care+")		4,505,550	S12	S1 AND S11		0	S11	(MH "Oncology Service, Hospital/OG/ST/TD/EC")		523	S10	S1 AND S9		3	S9	(MH "Academic Medical Centers+")		65,856	S8	S3 OR S5 OR S7		49	S7	S1 AND S6		44	S6	(MH "Outcome Assessment (Health Care)+") OR (MH "Outcome and Process Assessment (Health Care)+")		631,762	S5	S1 AND S4		3	S4	(MH "Referral and Consultation+")		52,940	S3	S1 AND S2		5	S2	TX specialist OR AB specialist OR TI specialist		97,872	S1	(MM "Gestational Trophoblastic Disease")	Limiters - Date of Publication from:	257
#	Query	Limiters/Expanders	Results																																																										
S14	S1 AND S13		147																																																										
S13	(MH "Quality of Health Care+")		4,505,550																																																										
S12	S1 AND S11		0																																																										
S11	(MH "Oncology Service, Hospital/OG/ST/TD/EC")		523																																																										
S10	S1 AND S9		3																																																										
S9	(MH "Academic Medical Centers+")		65,856																																																										
S8	S3 OR S5 OR S7		49																																																										
S7	S1 AND S6		44																																																										
S6	(MH "Outcome Assessment (Health Care)+") OR (MH "Outcome and Process Assessment (Health Care)+")		631,762																																																										
S5	S1 AND S4		3																																																										
S4	(MH "Referral and Consultation+")		52,940																																																										
S3	S1 AND S2		5																																																										
S2	TX specialist OR AB specialist OR TI specialist		97,872																																																										
S1	(MM "Gestational Trophoblastic Disease")	Limiters - Date of Publication from:	257																																																										

	20070101-20121231
Other/Secondary Resources Searched	Cochrane (incl. in Medline); TRIP Database; UpToDate; Ebsco Discovery federated search; NICE; Cancer Guideline Resource Centre
Search Strategy: Other resources	
Comments	
Date	



## Question 5

Clinical Question																																																					
For women with partial and complete molar pregnancy, what clinical and human chorionic gonadotropin monitoring protocol should be carried out to ensure they have been fully followed up and require no further therapy or monitoring?																																																					
PICO																																																					
Population/Problem	Women with partial or complete molar pregnancy																																																				
Intervention/Indicator or	Monitoring investigation – hCG levels																																																				
Comparator/Control	-																																																				
Outcome	Do not require further therapy or monitoring																																																				
Is the question specific to any of the categories below?																																																					
GENDER	AGE GROUP																																																				
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>																																																				
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>																																																				
	Adolescent (13 – 18 years) <input type="checkbox"/>																																																				
	Adult (19 – 65 years) <input type="checkbox"/>																																																				
	Aged (> 65 years) <input type="checkbox"/>																																																				
	DATE OF PUBLICATION																																																				
	Current year only <input type="checkbox"/>																																																				
	0 – 5 years <input type="checkbox"/>																																																				
	> 5 years <input checked="" type="checkbox"/>																																																				
Question Type																																																					
Therapy/Intervention <input type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>																																																				
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>																																																				
	Diagnosis <input checked="" type="checkbox"/>																																																				
	Other: <input type="checkbox"/>																																																				
	Prognosis/Prediction <input type="checkbox"/>																																																				
Search Strategy																																																					
Primary Database(s) Searched	Medline																																																				
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S17</td> <td>S14 OR S16</td> <td></td> <td>47</td> </tr> <tr> <td>S16</td> <td>S4 AND S11 AND S15</td> <td></td> <td>7</td> </tr> <tr> <td>S15</td> <td>(MH "Risk Assessment+")</td> <td></td> <td>157,209</td> </tr> <tr> <td>S14</td> <td>S9 OR S13</td> <td></td> <td>45</td> </tr> <tr> <td>S13</td> <td>S10 AND S11</td> <td>Limiters - Date of Publication from: 20020101-20121231</td> <td>25</td> </tr> <tr> <td>S12</td> <td>S10 AND S11</td> <td></td> <td>69</td> </tr> <tr> <td>S11</td> <td>(MH "Neoplasm Recurrence, Local")</td> <td></td> <td>76,002</td> </tr> <tr> <td>S10</td> <td>(MM "Hydatidiform Mole+")</td> <td></td> <td>3,337</td> </tr> <tr> <td>S9</td> <td>S5 OR S7</td> <td>Limiters - Date of Publication from: 20070101-20121231</td> <td>22</td> </tr> <tr> <td>S8</td> <td>S5 OR S7</td> <td></td> <td>85</td> </tr> <tr> <td>S7</td> <td>S5 AND S6</td> <td></td> <td>2</td> </tr> <tr> <td>S6</td> <td>SU monitor*</td> <td></td> <td>164,341</td> </tr> </tbody> </table>	#	Query	Limiters/Expanders	Results	S17	S14 OR S16		47	S16	S4 AND S11 AND S15		7	S15	(MH "Risk Assessment+")		157,209	S14	S9 OR S13		45	S13	S10 AND S11	Limiters - Date of Publication from: 20020101-20121231	25	S12	S10 AND S11		69	S11	(MH "Neoplasm Recurrence, Local")		76,002	S10	(MM "Hydatidiform Mole+")		3,337	S9	S5 OR S7	Limiters - Date of Publication from: 20070101-20121231	22	S8	S5 OR S7		85	S7	S5 AND S6		2	S6	SU monitor*		164,341
#	Query	Limiters/Expanders	Results																																																		
S17	S14 OR S16		47																																																		
S16	S4 AND S11 AND S15		7																																																		
S15	(MH "Risk Assessment+")		157,209																																																		
S14	S9 OR S13		45																																																		
S13	S10 AND S11	Limiters - Date of Publication from: 20020101-20121231	25																																																		
S12	S10 AND S11		69																																																		
S11	(MH "Neoplasm Recurrence, Local")		76,002																																																		
S10	(MM "Hydatidiform Mole+")		3,337																																																		
S9	S5 OR S7	Limiters - Date of Publication from: 20070101-20121231	22																																																		
S8	S5 OR S7		85																																																		
S7	S5 AND S6		2																																																		
S6	SU monitor*		164,341																																																		

Other/Secondary Resources Searched	S4	(MM "Gestational Trophoblastic Disease+")	7,508
	S3	S1 AND S2	33,214
	S2	( T1 mole* OR molar* OR "gestational trophoblastic" ) OR ( AB mole* OR molar* OR "gestational trophoblastic" )	1,292,273
	Cochrane (incl. in Medline); TRIP Database; UpToDate; Ebsco Discovery federated search		
Search Strategy: Other Resources			
Comments			
Date			

# Staging

## Question 6

Clinical Question			
For women with Gestational Trophoblastic Neoplasia (GTN), what investigations should be done to accurately stage GTN?			
PICO			
Population/Problem	Women with confirmed GTN		
Intervention/Indication or	Chest X-ray (CXR), liver ultrasound (US), transvaginal ultrasound (TVU), Magnetic Resonance Imaging (MRI) brain (if Lung metastases), Computed Tomography – Thorax, Abdomen and Pelvis (CT-TAP) (if abnormality on chest x-ray or liver ultrasound)		
Comparator/Control			
Outcome	To determine extent of disease To determine chemotherapy regimen		
Is the question specific to any of the categories below?			
GENDER	AGE GROUP	DATE OF PUBLICATION	
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>	
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input checked="" type="checkbox"/>	
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input type="checkbox"/>	
	Adult (19 – 65 years) <input type="checkbox"/>		
	Aged (> 65 years) <input type="checkbox"/>		
Question Type			
Therapy/Intervention <input type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input checked="" type="checkbox"/>
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:	
Search Strategy			
Primary Database(s) Searched	Medline		
Search Strategy	#	Query	Limiters/Expanders
	S21	S9 OR S15 OR S18 OR S19	Limiters - Date of Publication: 20130101-20141231
	S20	S9 OR S15 OR S18 OR S19	463
	S19	S8 AND S17	28
	S18	S8 AND S15	9
	S17	S5 AND S16	1,235
	S16	( TI x-ray OR ultraso* OR tomog* OR imaging ) OR ( AB x-ray OR ultraso* OR tomog* OR imaging )	1,570,758
	S15	S5 AND S14	358
	S14	S10 OR S11 OR S12 OR S13	378,089
	S13	MH "Ultrasonography"	62,658
	S12	MH "Positron-Emission Tomography"	31,985
	S11	MH "Magnetic Resonance Imaging"	279,517
	S10	MM "Diagnostic Imaging"	16,877
	S9	S5 AND S8	114
	S8	S6 OR S7	55,627
	S7	TI staging OR AB staging	53,753
	S6	MM "Neoplasm Staging"	5,456
	S5	S1 OR S2 OR S3 OR S4	9,904
	S4	TI gestational N2 trophoblastic OR AB gestational N2 trophoblastic	2,048
	S3	(MM "Gestational Trophoblastic Disease+") OR (MM "Trophoblastic	9,213

	S2	Neoplasms+") ( TI (hydatidiform OR invasive) N2 mole ) OR ( AB (hydatidiform OR invasive) N2 mole )	2,616
	S1	(MM "Hydatidiform Mole+")	3,441
Other/Secondary Resources Searched			
Search Strategy: Other Resources	Cochrane (incl. in Medline); TRIP Database; UpToDate; MD Consult; Ebsco Discovery federated search		
Comments			
Date			

## Question 7

<b>Clinical Question</b>																																																															
For women with gestational trophoblastic neoplasia (GTN), what risk scoring system should be used to stage GTN?																																																															
<b>PICO</b>																																																															
Population/Problem	Women with confirmed GTN																																																														
Intervention/Indicator	Staging system																																																														
Comparator/Control	-																																																														
Outcome	Accurate staging of GTN																																																														
<b>Is the question specific to any of the categories below?</b>																																																															
<b>GENDER</b>	<b>AGE GROUP</b>	<b>DATE OF PUBLICATION</b>																																																													
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																																													
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>																																																													
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>																																																													
	Adult (19 – 65 years) <input type="checkbox"/>																																																														
	Aged (> 65 years) <input type="checkbox"/>																																																														
<b>Question Type</b>																																																															
Therapy/Intervention <input type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input checked="" type="checkbox"/>																																																												
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																																													
<b>Search Strategy</b>																																																															
Primary Database(s) Searched	Medline																																																														
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S15</td> <td>S2 AND S14</td> <td></td> <td>1</td> </tr> <tr> <td>S14</td> <td>S1 AND S13</td> <td></td> <td>23</td> </tr> <tr> <td>S13</td> <td>TI "Charing Cross" OR AB "Charing Cross"</td> <td></td> <td>214</td> </tr> <tr> <td>S12</td> <td>S6 OR S7</td> <td>Limiters - Date of Publication from: 20070101-20121231</td> <td>64</td> </tr> <tr> <td>S11</td> <td>S9 AND S10</td> <td></td> <td>22</td> </tr> <tr> <td>S10</td> <td>.AB "International Federation of Obstetrics and Gynecology" OR FIGO</td> <td>Limiters - Date of Publication from: 20070101-20121231</td> <td>1,659</td> </tr> <tr> <td>S9</td> <td>S6 OR S7</td> <td></td> <td>158</td> </tr> <tr> <td>S8</td> <td>S6 AND S7</td> <td></td> <td>30</td> </tr> <tr> <td>S7</td> <td>S1 AND S4</td> <td></td> <td>136</td> </tr> <tr> <td>S6</td> <td>S1 AND S5</td> <td></td> <td>52</td> </tr> <tr> <td>S5</td> <td>TI staging* OR AB staging*</td> <td></td> <td>48,027</td> </tr> <tr> <td>S4</td> <td>(MH "Neoplasm Staging")</td> <td></td> <td>110,181</td> </tr> <tr> <td>S3</td> <td>S1 AND S2</td> <td></td> <td>6</td> </tr> <tr> <td>S2</td> <td>(MM "Neoplasm Staging")</td> <td></td> <td>5,005</td> </tr> </tbody> </table>			#	Query	Limiters/Expanders	Results	S15	S2 AND S14		1	S14	S1 AND S13		23	S13	TI "Charing Cross" OR AB "Charing Cross"		214	S12	S6 OR S7	Limiters - Date of Publication from: 20070101-20121231	64	S11	S9 AND S10		22	S10	.AB "International Federation of Obstetrics and Gynecology" OR FIGO	Limiters - Date of Publication from: 20070101-20121231	1,659	S9	S6 OR S7		158	S8	S6 AND S7		30	S7	S1 AND S4		136	S6	S1 AND S5		52	S5	TI staging* OR AB staging*		48,027	S4	(MH "Neoplasm Staging")		110,181	S3	S1 AND S2		6	S2	(MM "Neoplasm Staging")		5,005
#	Query	Limiters/Expanders	Results																																																												
S15	S2 AND S14		1																																																												
S14	S1 AND S13		23																																																												
S13	TI "Charing Cross" OR AB "Charing Cross"		214																																																												
S12	S6 OR S7	Limiters - Date of Publication from: 20070101-20121231	64																																																												
S11	S9 AND S10		22																																																												
S10	.AB "International Federation of Obstetrics and Gynecology" OR FIGO	Limiters - Date of Publication from: 20070101-20121231	1,659																																																												
S9	S6 OR S7		158																																																												
S8	S6 AND S7		30																																																												
S7	S1 AND S4		136																																																												
S6	S1 AND S5		52																																																												
S5	TI staging* OR AB staging*		48,027																																																												
S4	(MH "Neoplasm Staging")		110,181																																																												
S3	S1 AND S2		6																																																												
S2	(MM "Neoplasm Staging")		5,005																																																												

	S1	(MM "Gestational Trophoblastic Disease+")	7,515
Other/Secondary Resources Searched	Cochrane (incl. in Medline); TRIP Database; UpToDate; MD Consult; Ebsco Discovery federated search		
Search Strategy: Other Resources			
Comments			
Date			

## Treatment

### Question 8

Clinical Question																	
For women with gestational trophoblastic neoplasia, what are the clinical indicators to diagnose GTN warranting chemotherapy?																	
PICO																	
Population/Problem	Women with GTN																
Intervention/Indicator	Clinical indicators																
Comparator/Control	-																
Outcome	Commencement of chemotherapy																
Is the question specific to any of the categories below?																	
GENDER	AGE GROUP	DATE OF PUBLICATION															
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>															
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>															
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>															
	Adult (19 – 65 years) <input type="checkbox"/>																
	Aged (> 65 years) <input type="checkbox"/>																
Question Type																	
Therapy/Intervention <input checked="" type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>														
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:															
Search Strategy																	
Primary Database(s) Searched	Medline																
Search Strategy	<table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr style="background-color: #ffffcc;"> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S12</td> <td>S4 AND S9</td> <td>Limiters - Date of Publication: 20070101-20131231; Review Articles</td> <td>45</td> </tr> <tr> <td>S11</td> <td>S4 AND S9</td> <td>Limiters - Date of Publication: 20070101-20131231</td> <td>430</td> </tr> <tr> <td>S10</td> <td>S4 AND S9</td> <td></td> <td>2,556</td> </tr> </tbody> </table>	#	Query	Limiters/Expanders	Results	S12	S4 AND S9	Limiters - Date of Publication: 20070101-20131231; Review Articles	45	S11	S4 AND S9	Limiters - Date of Publication: 20070101-20131231	430	S10	S4 AND S9		2,556
#	Query	Limiters/Expanders	Results														
S12	S4 AND S9	Limiters - Date of Publication: 20070101-20131231; Review Articles	45														
S11	S4 AND S9	Limiters - Date of Publication: 20070101-20131231	430														
S10	S4 AND S9		2,556														

	S8	( T1 (etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA) ) OR ( AB (etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA) )	125,975
	S7	T1 chemotherap* OR AB chemotherap*	259,999
	S6	(MH "Antineoplastic Combined Chemotherapy Protocols")	98,889
	S5	(MH "Antineoplastic Agents+")	269,597
	S4	S1 OR S2 OR S3	11,579
	S3	(MM "Gestational Trophoblastic Disease+")	7,565
	S2	"gestational trophoblastic" N2 (neoplasm* OR tumor* OR tumour*)	520
Other/Secondary Resources Searched	UpToDate; Cochrane		
Search Strategy: Other Resources			
Comments			
Date			



## Question 9

Clinical Question																									
For patients with low-risk (FIGO 0-6) GTN, what is the optimal first-line chemotherapy regimen?																									
PICO																									
Population/Problem	Women with GTN																								
Intervention/Indicator	Chemotherapy regimens - Methotrexate / Folinic Acid - Actinomycin D																								
Comparator/Control	-																								
Outcome	5-year survival Recurrence Metastases Side-effects from chemotherapy Toxicity																								
Is the question specific to any of the categories below?																									
GENDER	AGE GROUP	DATE OF PUBLICATION																							
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																							
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input checked="" type="checkbox"/>																							
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input type="checkbox"/>																							
	Adult (19 – 65 years) <input type="checkbox"/>																								
	Aged (> 65 years) <input type="checkbox"/>																								
Question Type																									
Therapy/Intervention <input checked="" type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/> Prognosis/Prediction <input type="checkbox"/>																							
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																							
Search Strategy																									
Primary Database(s) Searched	Medline																								
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S15</td> <td>S5 AND S10</td> <td>Limiters - Date of Publication: 20120101-20131231; Review Articles</td> <td>62</td> </tr> <tr> <td>S14</td> <td>S5 AND S10</td> <td>Limiters - Review Articles</td> <td>770</td> </tr> <tr> <td>S13</td> <td>S5 AND S10</td> <td>Limiters - Date of Publication: 20120101-20131231; Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial</td> <td>5</td> </tr> <tr> <td>S12</td> <td>S5 AND S10</td> <td>Limiters - Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial</td> <td>101</td> </tr> <tr> <td>S11</td> <td>S5 AND S10</td> <td></td> <td>4,231</td> </tr> </tbody> </table>	#	Query	Limiters/Expanders	Results	S15	S5 AND S10	Limiters - Date of Publication: 20120101-20131231; Review Articles	62	S14	S5 AND S10	Limiters - Review Articles	770	S13	S5 AND S10	Limiters - Date of Publication: 20120101-20131231; Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial	5	S12	S5 AND S10	Limiters - Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial	101	S11	S5 AND S10		4,231
#	Query	Limiters/Expanders	Results																						
S15	S5 AND S10	Limiters - Date of Publication: 20120101-20131231; Review Articles	62																						
S14	S5 AND S10	Limiters - Review Articles	770																						
S13	S5 AND S10	Limiters - Date of Publication: 20120101-20131231; Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial	5																						
S12	S5 AND S10	Limiters - Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial	101																						
S11	S5 AND S10		4,231																						

S10	S6 OR S7 OR S8 OR S9		634,335
S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA)		212,216
S8	chemotherap*		316,118
S7	(MH "Antineoplastic Combined Chemotherapy Protocols")		98,936
S6	(MH "Antineoplastic Agents+")		269,772
S5	S1 OR S2 OR S3 OR S4		33,189
S4	((hydatidiform or invasive) and mole*)		24,412
S3	(GTT or GTD or GTN)		3,360
S2	("gestational trophoblastic" N2 (neoplasm* or tumor* or tumour* or disease*))		1,819
S1	(MH "Gestational Trophoblastic Disease+")		10,221

Other/Secondary Resources Searched

UPTODATE; COCHRANE; NCI

Search Strategy:  
Other Resources

Comments

Date

## Question 10

<b>Clinical Question</b>																						
For women with high-risk (FIGO ≥7) GTN, what is the optimal first-line chemotherapy regimen?																						
<b>PICO</b>																						
Population/Problem	Women with GTN																					
Intervention/Indicator	Chemotherapy regimens - EMA-CO - EP/EMA chemotherapy - TE/TP chemotherapy																					
Comparator/Control	-																					
Outcome	5-year survival Recurrence Metastases																					
<b>Is the question specific to any of the categories below?</b>																						
<b>GENDER</b>	<b>AGE GROUP</b>	<b>DATE OF PUBLICATION</b>																				
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																				
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input checked="" type="checkbox"/>																				
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input type="checkbox"/>																				
	Adult (19 – 65 years) <input type="checkbox"/>																					
	Aged (> 65 years) <input type="checkbox"/>																					
<b>Question Type</b>																						
Therapy/Intervention <input checked="" type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																			
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other: <input type="checkbox"/>																				
<b>Search Strategy</b>																						
Primary Database(s) Searched	Medline																					
Search Strategy	<table border="1"> <thead> <tr> <th></th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S15</td> <td>S5 AND S10</td> <td>Limiters - Date of Publication: 20120101-20131231; Review Articles</td> <td>62</td> </tr> <tr> <td>S14</td> <td>S5 AND S10</td> <td>Limiters - Review Articles</td> <td>770</td> </tr> <tr> <td>S13</td> <td>S5 AND S10</td> <td>Limiters - Date of Publication: 20120101-20131231; Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial</td> <td>5</td> </tr> <tr> <td>S12</td> <td>S5 AND S10</td> <td>Limiters - Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial</td> <td>101</td> </tr> </tbody> </table>			Query	Limiters/Expanders	Results	S15	S5 AND S10	Limiters - Date of Publication: 20120101-20131231; Review Articles	62	S14	S5 AND S10	Limiters - Review Articles	770	S13	S5 AND S10	Limiters - Date of Publication: 20120101-20131231; Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial	5	S12	S5 AND S10	Limiters - Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial	101
	Query	Limiters/Expanders	Results																			
S15	S5 AND S10	Limiters - Date of Publication: 20120101-20131231; Review Articles	62																			
S14	S5 AND S10	Limiters - Review Articles	770																			
S13	S5 AND S10	Limiters - Date of Publication: 20120101-20131231; Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial	5																			
S12	S5 AND S10	Limiters - Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Multicenter Study, Randomized Controlled Trial	101																			

	S10	S6 OR S7 OR S8 OR S9	634,335
	S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA)	212,216
	S8	chemotherap*	316,118
	S7	(MH "Antineoplastic Combined Chemotherapy Protocols")	98,936
	S6	(MH "Antineoplastic Agents+")	269,772
	S5	S1 OR S2 OR S3 OR S4	33,189
	S4	((hydatidiform or invasive) and mole*)	24,412
	S3	(GTT or GTD or GTN)	3,360
	S2	("gestational trophoblastic" N2 (neoplasm* or tumor* or tumour* or disease*))	1,819
	S1	(MH "Gestational Trophoblastic	10,221
Other/Secondary Resources Searched	UpToDate; cochrane; NCI		
Search Strategy: Other Resources			
Comments			
Date			

## Question 11

Clinical Question																																																			
For women with low-risk gestational trophoblastic neoplasia undergoing chemotherapy (first-course), what is the recommended course of action for observing and managing bleeding?																																																			
PICO																																																			
Population/Problem	Women with GTN undergoing chemotherapy																																																		
Intervention/Indicator	Observation & management of bleeding																																																		
Comparator/Control	-																																																		
Outcome	Optimum management																																																		
Is the question specific to any of the categories below?																																																			
GENDER	AGE GROUP	DATE OF PUBLICATION																																																	
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																																	
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>																																																	
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>																																																	
	Adult (19 – 65 years) <input type="checkbox"/>																																																		
	Aged (> 65 years) <input type="checkbox"/>																																																		
Question Type																																																			
Therapy/Intervention <input checked="" type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																																
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																																	
Search Strategy																																																			
Primary Database(s) Searched	Medline																																																		
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S19</td> <td>S11 AND S14</td> <td>Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Therapy - High Sensitivity</td> <td>43</td> </tr> <tr> <td>S18</td> <td>S16 AND S17</td> <td></td> <td>4</td> </tr> <tr> <td>S17</td> <td>MM "Uterine Hemorrhage therapy"</td> <td></td> <td>453</td> </tr> <tr> <td>S16</td> <td>S11 AND S14</td> <td>Limiters - Date of Publication: 20020101-20131231</td> <td>84</td> </tr> <tr> <td>S15</td> <td>S11 AND S14</td> <td></td> <td>110</td> </tr> <tr> <td>S14</td> <td>S12 OR S13</td> <td></td> <td>Display</td> </tr> <tr> <td>S13</td> <td>(vagina* N2 (bleed* OR hemorrhag* OR haemorrhag*))</td> <td>Limiters - Date of Publication: 20020101-20131231</td> <td>Display</td> </tr> <tr> <td>S12</td> <td>(MH "Uterine Hemorrhage+")</td> <td></td> <td>Display</td> </tr> <tr> <td>S11</td> <td>S5 AND S10</td> <td></td> <td>Display</td> </tr> <tr> <td>S10</td> <td>S6 OR S7 OR S8 OR S9</td> <td></td> <td>635,606</td> </tr> <tr> <td>S9</td> <td>(etoposide or methotrexate or</td> <td></td> <td>212,517</td> </tr> </tbody> </table>			#	Query	Limiters/Expanders	Results	S19	S11 AND S14	Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Therapy - High Sensitivity	43	S18	S16 AND S17		4	S17	MM "Uterine Hemorrhage therapy"		453	S16	S11 AND S14	Limiters - Date of Publication: 20020101-20131231	84	S15	S11 AND S14		110	S14	S12 OR S13		Display	S13	(vagina* N2 (bleed* OR hemorrhag* OR haemorrhag*))	Limiters - Date of Publication: 20020101-20131231	Display	S12	(MH "Uterine Hemorrhage+")		Display	S11	S5 AND S10		Display	S10	S6 OR S7 OR S8 OR S9		635,606	S9	(etoposide or methotrexate or		212,517
#	Query	Limiters/Expanders	Results																																																
S19	S11 AND S14	Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Therapy - High Sensitivity	43																																																
S18	S16 AND S17		4																																																
S17	MM "Uterine Hemorrhage therapy"		453																																																
S16	S11 AND S14	Limiters - Date of Publication: 20020101-20131231	84																																																
S15	S11 AND S14		110																																																
S14	S12 OR S13		Display																																																
S13	(vagina* N2 (bleed* OR hemorrhag* OR haemorrhag*))	Limiters - Date of Publication: 20020101-20131231	Display																																																
S12	(MH "Uterine Hemorrhage+")		Display																																																
S11	S5 AND S10		Display																																																
S10	S6 OR S7 OR S8 OR S9		635,606																																																
S9	(etoposide or methotrexate or		212,517																																																

	dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA)		
S8	chemotherap*		316,767
S7	(MH "Antineoplastic Combined Chemotherapy Protocols")		99,084
S6	(MH "Antineoplastic Agents+")		270,378
S5	S1 OR S2 OR S3 OR S4		33,265
S4	((hydatidiform or invasive) and mole*)		24,477
S3	(GTT or GTD or GTN)		3,368
S2	("gestational trophoblastic" N2 (neoplasm* or tumor* or tumour* or disease*))		1,821
S1	(MH "Gestational Trophoblastic Disease+")		10,226
Other/Secondary Resources Searched	Cochrane; UpToDate; eds		
Search Strategy: Other Resources			
Comments			
Date			

## Question 12

Clinical Question																																											
For women with gestational trophoblastic neoplasia, what are the appropriate investigations to monitor response to chemotherapy and follow-up?																																											
PICO																																											
Population/Problem	Women with GTN																																										
Intervention/Indication or	hCG levels																																										
Comparator/Control	-																																										
Outcome	Response to chemotherapy and follow-up																																										
Is the question specific to any of the categories below?																																											
GENDER	AGE GROUP	DATE OF PUBLICATION																																									
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																									
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>																																									
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>																																									
	Adult (19 – 65 years) <input type="checkbox"/>																																										
	Aged (> 65 years) <input type="checkbox"/>																																										
Question Type																																											
Therapy/Intervention <input checked="" type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																								
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																									
Search Strategy																																											
Primary Database(s) Searched	Medline																																										
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S19</td> <td>S14 not s15</td> <td>Limiters - Date of Publication: 20070101-20131231</td> <td>97</td> </tr> <tr> <td>S18</td> <td>S16 AND S17</td> <td></td> <td>13</td> </tr> <tr> <td>S17</td> <td>(MM "Chorionic Gonadotropin, beta Subunit, Human")</td> <td></td> <td>1,077</td> </tr> <tr> <td>S16</td> <td>S14 not s15</td> <td></td> <td>168</td> </tr> <tr> <td>S15</td> <td>S11 AND S12</td> <td>Limiters - Date of Publication: 20020101-20131231; Publication Type: Case Reports</td> <td>100</td> </tr> <tr> <td>S14</td> <td>S11 AND S12</td> <td>Limiters - Date of Publication: 20020101-20131231</td> <td>268</td> </tr> <tr> <td>S13</td> <td>S11 AND S12</td> <td></td> <td>654</td> </tr> <tr> <td>S12</td> <td>(MM "Chorionic Gonadotropin, beta Subunit, Human") OR "hcg"</td> <td></td> <td>21,068</td> </tr> <tr> <td>S11</td> <td>S5 AND S10</td> <td></td> <td>4,260</td> </tr> </tbody> </table>			#	Query	Limiters/Expanders	Results	S19	S14 not s15	Limiters - Date of Publication: 20070101-20131231	97	S18	S16 AND S17		13	S17	(MM "Chorionic Gonadotropin, beta Subunit, Human")		1,077	S16	S14 not s15		168	S15	S11 AND S12	Limiters - Date of Publication: 20020101-20131231; Publication Type: Case Reports	100	S14	S11 AND S12	Limiters - Date of Publication: 20020101-20131231	268	S13	S11 AND S12		654	S12	(MM "Chorionic Gonadotropin, beta Subunit, Human") OR "hcg"		21,068	S11	S5 AND S10		4,260
#	Query	Limiters/Expanders	Results																																								
S19	S14 not s15	Limiters - Date of Publication: 20070101-20131231	97																																								
S18	S16 AND S17		13																																								
S17	(MM "Chorionic Gonadotropin, beta Subunit, Human")		1,077																																								
S16	S14 not s15		168																																								
S15	S11 AND S12	Limiters - Date of Publication: 20020101-20131231; Publication Type: Case Reports	100																																								
S14	S11 AND S12	Limiters - Date of Publication: 20020101-20131231	268																																								
S13	S11 AND S12		654																																								
S12	(MM "Chorionic Gonadotropin, beta Subunit, Human") OR "hcg"		21,068																																								
S11	S5 AND S10		4,260																																								

S10	S6 OR S7 OR S8 OR S9	637,625
S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA)	212,945
S8	chemotherap*	317,852
S7	(MH "Antineoplastic Combined Chemotherapy Protocols")	99,380
S6	(MH "Antineoplastic Agents+")	271,393
S5	S1 OR S2 OR S3 OR S4	33,387
S4	((hydatidiform or invasive) and mole*)	24,585
S3	(GTT or GTD or GTN)	3,378
S2	("gestational trophoblastic" N2 (neoplasm* or tumor* or tumour* or disease*))	1,825
S1	(MH "Gestational Trophoblastic Disease+")	10,239

Other/Secondary Resources Searched

Uptodate; Cochrane

Search Strategy: Other Resources

Comments

Date



## Question 13

Clinical Question																																													
For women with low-risk gestational trophoblastic neoplasia what are the indicators to determine switching treatments from first-line chemotherapy?																																													
PICO																																													
Population/Problem	Women with low-risk GTN undergoing first-line chemotherapy																																												
Intervention/Indicator	Indicators - plateau in hCG - toxicity																																												
Comparator/Control																																													
Outcome	Switch from first-line treatment																																												
Is the question specific to any of the categories below?																																													
GENDER	AGE GROUP	DATE OF PUBLICATION																																											
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																											
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>																																											
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>																																											
	Adult (19 – 65 years) <input type="checkbox"/>																																												
	Aged (> 65 years) <input type="checkbox"/>																																												
Question Type																																													
Therapy/Intervention <input checked="" type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																										
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																											
Search Strategy																																													
Primary Database(s) Searched	Medline																																												
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S23</td> <td>S11 AND S12</td> <td>Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Prognosis - Best Balance</td> <td>25</td> </tr> <tr> <td>S22</td> <td>S11 AND S12</td> <td>Limiters - Clinical Queries: Prognosis - Best Balance</td> <td>34</td> </tr> <tr> <td>S21</td> <td>S13 AND S20</td> <td></td> <td>3</td> </tr> <tr> <td>S20</td> <td>MM "Drug Resistance, Neoplasm"</td> <td></td> <td>10,046</td> </tr> <tr> <td>S19</td> <td>S13 AND S18</td> <td></td> <td>32</td> </tr> <tr> <td>S18</td> <td>AB fail* OR resist*</td> <td>Limiters - Date of Publication: 20020101-20131231</td> <td>715,060</td> </tr> <tr> <td>S17</td> <td>S13 AND S15</td> <td>Limiters - Date of Publication: 20020101-20131231</td> <td>28</td> </tr> <tr> <td>S16</td> <td>S13 AND S15</td> <td></td> <td>41</td> </tr> <tr> <td>S15</td> <td>S11 AND S14</td> <td></td> <td>604</td> </tr> <tr> <td>S14</td> <td>( TI "second-line" OR "second line" OR combination ) OR ( AB "second-line" OR "second line" OR combination )</td> <td></td> <td>635,089</td> </tr> </tbody> </table>	#	Query	Limiters/Expanders	Results	S23	S11 AND S12	Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Prognosis - Best Balance	25	S22	S11 AND S12	Limiters - Clinical Queries: Prognosis - Best Balance	34	S21	S13 AND S20		3	S20	MM "Drug Resistance, Neoplasm"		10,046	S19	S13 AND S18		32	S18	AB fail* OR resist*	Limiters - Date of Publication: 20020101-20131231	715,060	S17	S13 AND S15	Limiters - Date of Publication: 20020101-20131231	28	S16	S13 AND S15		41	S15	S11 AND S14		604	S14	( TI "second-line" OR "second line" OR combination ) OR ( AB "second-line" OR "second line" OR combination )		635,089
#	Query	Limiters/Expanders	Results																																										
S23	S11 AND S12	Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Prognosis - Best Balance	25																																										
S22	S11 AND S12	Limiters - Clinical Queries: Prognosis - Best Balance	34																																										
S21	S13 AND S20		3																																										
S20	MM "Drug Resistance, Neoplasm"		10,046																																										
S19	S13 AND S18		32																																										
S18	AB fail* OR resist*	Limiters - Date of Publication: 20020101-20131231	715,060																																										
S17	S13 AND S15	Limiters - Date of Publication: 20020101-20131231	28																																										
S16	S13 AND S15		41																																										
S15	S11 AND S14		604																																										
S14	( TI "second-line" OR "second line" OR combination ) OR ( AB "second-line" OR "second line" OR combination )		635,089																																										

S13	S11 AND S12		90
S12	( TI "first-line" OR "first line" ) OR ( AB "first-line" OR "first line" )		39,758
S11	S5 AND S10		4,266
S10	S6 OR S7 OR S8 OR S9		638,286
S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA)		213,096
S8	chemotherap*		318,251
S7	(MH "Antineoplastic Combined Chemotherapy Protocols")		99,445
S6	(MH "Antineoplastic Agents+")		271,636
S5	S1 OR S2 OR S3 OR S4		33,433
S4	((hydattidiform or invasive) and mole*)		24,626
S3	(GTT or GTD or GTN)		3,381
S2	("gestational trophoblastic" N2 (neoplasm* or tumor* or tumour* or disease*))		1,828
S1	(MH "Gestational Trophoblastic Disease+")		10,239

Other/Secondary Resources Searched

Search Strategy: Other Resources

Comments

Date


## Question 14a

Clinical Question																																																													
For women with low-risk gestational trophoblastic neoplasia who have not responded or have relapsed from single agent treatment (methotrexate or actinomycin D) or have relapsed following normalisation of hCG after completion of single agent treatment, what is the next line treatment?																																																													
PICO																																																													
Population/Problem	Women with low-risk invasive GTN who have not responded to single agent treatment or relapsed.																																																												
Intervention/Indicator	Next line treatment chemotherapy																																																												
Comparator/Control	-																																																												
Outcome	5-year survival																																																												
Is the question specific to any of the categories below?																																																													
GENDER	AGE GROUP	DATE OF PUBLICATION																																																											
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																																											
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input checked="" type="checkbox"/>																																																											
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input type="checkbox"/>																																																											
	Adult (19 – 65 years) <input type="checkbox"/>																																																												
	Aged (> 65 years) <input type="checkbox"/>																																																												
Question Type																																																													
Therapy/Intervention <input checked="" type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																																										
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																																											
Search Strategy																																																													
Primary Database(s) Searched	Medline																																																												
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S22</td> <td>S19 AND S20</td> <td>Limiters - Date of Publication: 20130101-20141231</td> <td>9</td> </tr> <tr> <td>S21</td> <td>S19 AND S20</td> <td></td> <td>89</td> </tr> <tr> <td>S20</td> <td>TI "low\$risk" OR AB "low\$risk"</td> <td></td> <td>36,813</td> </tr> <tr> <td>S19</td> <td>S17 OR S18</td> <td></td> <td>916</td> </tr> <tr> <td>S18</td> <td>S11 AND S16</td> <td></td> <td>201</td> </tr> <tr> <td>S17</td> <td>S11 AND S15</td> <td></td> <td>755</td> </tr> <tr> <td>S16</td> <td>(MH "Drug Resistance, Neoplasm")</td> <td></td> <td>28,030</td> </tr> <tr> <td>S15</td> <td>S13 OR S14</td> <td></td> <td>823,822</td> </tr> <tr> <td>S14</td> <td>( TI "second\$line" OR combination* ) OR ( AB "second\$line" OR combination* )</td> <td></td> <td>792,830</td> </tr> <tr> <td>S13</td> <td>TI "first\$line" OR AB "first\$line"</td> <td></td> <td>44,876</td> </tr> <tr> <td>S12</td> <td>( TI fail* OR resist* ) OR ( AB fail* OR resist* )</td> <td></td> <td>1,541,483</td> </tr> <tr> <td>S11</td> <td>S5 AND S10</td> <td></td> <td>4,599</td> </tr> <tr> <td>S10</td> <td>S6 OR S7 OR S8 OR S9</td> <td></td> <td>681,272</td> </tr> <tr> <td>S9</td> <td>(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or</td> <td></td> <td>222,372</td> </tr> </tbody> </table>	#	Query	Limiters/Expanders	Results	S22	S19 AND S20	Limiters - Date of Publication: 20130101-20141231	9	S21	S19 AND S20		89	S20	TI "low\$risk" OR AB "low\$risk"		36,813	S19	S17 OR S18		916	S18	S11 AND S16		201	S17	S11 AND S15		755	S16	(MH "Drug Resistance, Neoplasm")		28,030	S15	S13 OR S14		823,822	S14	( TI "second\$line" OR combination* ) OR ( AB "second\$line" OR combination* )		792,830	S13	TI "first\$line" OR AB "first\$line"		44,876	S12	( TI fail* OR resist* ) OR ( AB fail* OR resist* )		1,541,483	S11	S5 AND S10		4,599	S10	S6 OR S7 OR S8 OR S9		681,272	S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or		222,372
#	Query	Limiters/Expanders	Results																																																										
S22	S19 AND S20	Limiters - Date of Publication: 20130101-20141231	9																																																										
S21	S19 AND S20		89																																																										
S20	TI "low\$risk" OR AB "low\$risk"		36,813																																																										
S19	S17 OR S18		916																																																										
S18	S11 AND S16		201																																																										
S17	S11 AND S15		755																																																										
S16	(MH "Drug Resistance, Neoplasm")		28,030																																																										
S15	S13 OR S14		823,822																																																										
S14	( TI "second\$line" OR combination* ) OR ( AB "second\$line" OR combination* )		792,830																																																										
S13	TI "first\$line" OR AB "first\$line"		44,876																																																										
S12	( TI fail* OR resist* ) OR ( AB fail* OR resist* )		1,541,483																																																										
S11	S5 AND S10		4,599																																																										
S10	S6 OR S7 OR S8 OR S9		681,272																																																										
S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or		222,372																																																										

	CHAMOCA)		
S8	chemotherap*		341,998
S7	(MH "Antineoplastic Combined Chemotherapy Protocols")		105,213
S6	(MH "Antineoplastic Agents+")		291,192
S5	S1 OR S2 OR S3 OR S4		36,550
S4	((hydatidiform or invasive) and mole*)		27,495
S3	(GTT or GTD or GTN)		3,565
S2	("gestational trophoblastic" N2 (neoplasm* or tumor* or tumour* or disease*))		1,914
S1	(MH "Gestational Trophoblastic Disease+")		10,418
Other/Secondary Resources Searched	UpToDate, Cochrane		
Search Strategy: Other Resources			
Comments			
Date	<input type="checkbox"/>		

## Question 14b

Clinical Question																																																															
For women with high-risk GTN who have not responded or have relapsed from firstline treatment, what is second-line treatment?																																																															
PICO																																																															
Population/Problem	Women with high-risk GTN who have not responded to first-line treatment																																																														
Intervention/Indicator	Second-line treatment chemotherapy																																																														
Comparator/Control	-																																																														
Outcome	5-year survival																																																														
Is the question specific to any of the categories below?																																																															
GENDER	AGE GROUP	DATE OF PUBLICATION																																																													
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																																													
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input checked="" type="checkbox"/>																																																													
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input type="checkbox"/>																																																													
	Adult (19 – 65 years) <input type="checkbox"/>																																																														
	Aged (> 65 years) <input type="checkbox"/>																																																														
Question Type																																																															
Therapy/Intervention <input checked="" type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																																												
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Other:																																																													
Search Strategy																																																															
Primary Database(s) Searched	Medline																																																														
Search Strategy	<table border="1"> <thead> <tr> <th>#</th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S22</td> <td>S19 AND S20</td> <td>Limiters - Date of Publication: 20130101-20141231</td> <td>13</td> </tr> <tr> <td>S21</td> <td>S19 AND S20</td> <td></td> <td>155</td> </tr> <tr> <td>S20</td> <td>TI "high\$risk" OR AB "high\$risk"</td> <td></td> <td>173,224</td> </tr> <tr> <td>S19</td> <td>S17 OR S18</td> <td></td> <td>916</td> </tr> <tr> <td>S18</td> <td>S11 AND S16</td> <td></td> <td>201</td> </tr> <tr> <td>S17</td> <td>S11 AND S15</td> <td></td> <td>755</td> </tr> <tr> <td>S16</td> <td>(MH "Drug Resistance, Neoplasm")</td> <td></td> <td>28,030</td> </tr> <tr> <td>S15</td> <td>S13 OR S14</td> <td></td> <td>823,822</td> </tr> <tr> <td>S14</td> <td>( TI "second\$line" OR combination* ) OR ( AB "second\$line" OR combination* )</td> <td></td> <td>792,830</td> </tr> <tr> <td>S13</td> <td>TI "first\$line" OR AB "first\$line"</td> <td></td> <td>44,876</td> </tr> <tr> <td>S12</td> <td>( TI fail* OR resist* ) OR ( AB fail* OR resist* )</td> <td></td> <td>1,541,483</td> </tr> <tr> <td>S11</td> <td>S5 AND S10</td> <td></td> <td>4,599</td> </tr> <tr> <td>S10</td> <td>S6 OR S7 OR S8 OR S9</td> <td></td> <td>681,272</td> </tr> <tr> <td>S9</td> <td>(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO</td> <td></td> <td>222,372</td> </tr> </tbody> </table>			#	Query	Limiters/Expanders	Results	S22	S19 AND S20	Limiters - Date of Publication: 20130101-20141231	13	S21	S19 AND S20		155	S20	TI "high\$risk" OR AB "high\$risk"		173,224	S19	S17 OR S18		916	S18	S11 AND S16		201	S17	S11 AND S15		755	S16	(MH "Drug Resistance, Neoplasm")		28,030	S15	S13 OR S14		823,822	S14	( TI "second\$line" OR combination* ) OR ( AB "second\$line" OR combination* )		792,830	S13	TI "first\$line" OR AB "first\$line"		44,876	S12	( TI fail* OR resist* ) OR ( AB fail* OR resist* )		1,541,483	S11	S5 AND S10		4,599	S10	S6 OR S7 OR S8 OR S9		681,272	S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO		222,372
#	Query	Limiters/Expanders	Results																																																												
S22	S19 AND S20	Limiters - Date of Publication: 20130101-20141231	13																																																												
S21	S19 AND S20		155																																																												
S20	TI "high\$risk" OR AB "high\$risk"		173,224																																																												
S19	S17 OR S18		916																																																												
S18	S11 AND S16		201																																																												
S17	S11 AND S15		755																																																												
S16	(MH "Drug Resistance, Neoplasm")		28,030																																																												
S15	S13 OR S14		823,822																																																												
S14	( TI "second\$line" OR combination* ) OR ( AB "second\$line" OR combination* )		792,830																																																												
S13	TI "first\$line" OR AB "first\$line"		44,876																																																												
S12	( TI fail* OR resist* ) OR ( AB fail* OR resist* )		1,541,483																																																												
S11	S5 AND S10		4,599																																																												
S10	S6 OR S7 OR S8 OR S9		681,272																																																												
S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO		222,372																																																												

	or EMA-CO or CHAMOCA)		
S8	chemotherap*		341,998
S7	(MH "Antineoplastic Combined Chemotherapy Protocols")		105,213
S6	(MH "Antineoplastic Agents+")		291,192
S5	S1 OR S2 OR S3 OR S4		36,550
S4	((hydattidiform or invasive) and mole*)		27,495
S3	(GTT or GTD or GTN)		3,565
S2	("gestational trophoblastic" N2 (neoplasm* or tumor* or tumour* or disease*))		1,914
S1	(MH "Gestational Trophoblastic Disease+")		10,418

Other/Secondary Resources Searched

Search Strategy: Other Resources

Comments

Date

UpToDate, Cochrane

## Question 15

Clinical Question																																														
For women with GTN, who are acutely ill with liver, brain or lung metastasis at presentation, what is the optimum chemotherapy regimen?																																														
PICO																																														
Population/Problem	Women with GTN who are acutely ill with liver, brain or lung metastases																																													
Intervention/Indicator	Management / treatment options - 2 days EP (Charing Cross protocol)																																													
Comparator/Control	-																																													
Outcome	Survival																																													
Is the question specific to any of the categories below?																																														
GENDER	AGE GROUP	DATE OF PUBLICATION																																												
Male <input type="checkbox"/>	Infant (0 – 23 months) <input type="checkbox"/>	Current year only <input type="checkbox"/>																																												
Female <input checked="" type="checkbox"/>	Child (2 – 12 years) <input type="checkbox"/>	0 – 5 years <input type="checkbox"/>																																												
	Adolescent (13 – 18 years) <input type="checkbox"/>	> 5 years <input checked="" type="checkbox"/>																																												
	Adult (19 – 65 years) <input type="checkbox"/>																																													
	Aged (> 65 years) <input type="checkbox"/>																																													
Question Type																																														
Therapy/Intervention <input type="checkbox"/>	Aetiology/Risk Factors <input type="checkbox"/>	Diagnosis <input checked="" type="checkbox"/>																																												
Frequency/Rate <input type="checkbox"/>	Phenomena <input type="checkbox"/>	Prognosis/Prediction <input type="checkbox"/>																																												
Other: <input type="checkbox"/>																																														
Search Strategy																																														
Primary Database(s) Searched	Medline																																													
Search Strategy	<table border="1"> <thead> <tr> <th></th> <th>Query</th> <th>Limiters/Expanders</th> <th>Results</th> </tr> </thead> <tbody> <tr> <td>S22</td> <td>S15 OR S17 OR S19</td> <td>Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Therapy - High Sensitivity</td> <td>19</td> </tr> <tr> <td>S21</td> <td>S15 OR S17 OR S19</td> <td>Limiters - Date of Publication: 20020101-20131231</td> <td>38</td> </tr> <tr> <td>S20</td> <td>S15 OR S17 OR S19</td> <td></td> <td>181</td> </tr> <tr> <td>S19</td> <td>S13 AND S18</td> <td></td> <td>28</td> </tr> <tr> <td>S18</td> <td>(MH "Liver Neoplasms+") OR (MH "Liver+")</td> <td></td> <td>472,017</td> </tr> <tr> <td>S17</td> <td>S13 AND S16</td> <td></td> <td>141</td> </tr> <tr> <td>S16</td> <td>(MH "Lung+") OR (MH "Lung Neoplasms+")</td> <td></td> <td>365,144</td> </tr> <tr> <td>S15</td> <td>S13 AND S14</td> <td></td> <td>49</td> </tr> <tr> <td>S14</td> <td>(MH "Brain+") OR (MH "Brain Neoplasms+")</td> <td></td> <td>1,019,886</td> </tr> <tr> <td>S13</td> <td>S11 AND S12</td> <td></td> <td>587</td> </tr> </tbody> </table>			Query	Limiters/Expanders	Results	S22	S15 OR S17 OR S19	Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Therapy - High Sensitivity	19	S21	S15 OR S17 OR S19	Limiters - Date of Publication: 20020101-20131231	38	S20	S15 OR S17 OR S19		181	S19	S13 AND S18		28	S18	(MH "Liver Neoplasms+") OR (MH "Liver+")		472,017	S17	S13 AND S16		141	S16	(MH "Lung+") OR (MH "Lung Neoplasms+")		365,144	S15	S13 AND S14		49	S14	(MH "Brain+") OR (MH "Brain Neoplasms+")		1,019,886	S13	S11 AND S12		587
	Query	Limiters/Expanders	Results																																											
S22	S15 OR S17 OR S19	Limiters - Date of Publication: 20020101-20131231; Clinical Queries: Therapy - High Sensitivity	19																																											
S21	S15 OR S17 OR S19	Limiters - Date of Publication: 20020101-20131231	38																																											
S20	S15 OR S17 OR S19		181																																											
S19	S13 AND S18		28																																											
S18	(MH "Liver Neoplasms+") OR (MH "Liver+")		472,017																																											
S17	S13 AND S16		141																																											
S16	(MH "Lung+") OR (MH "Lung Neoplasms+")		365,144																																											
S15	S13 AND S14		49																																											
S14	(MH "Brain+") OR (MH "Brain Neoplasms+")		1,019,886																																											
S13	S11 AND S12		587																																											

S11	S5 AND S10		4,273
S10	S6 OR S7 OR S8 OR S9		639,111
S9	(etoposide or methotrexate or dactinomycin or actinomycin or cyclophosphamide or vincristine or chlorambucil* or doxorubicin or melphalan or hydroxyurea or Hammond or Goldstein or EMA?CO or EMA-CO or CHAMOCA)		213,349
S8	chemotherap*		318,895
S7	(MH "Antineoplastic Combined Chemotherapy Protocols")		99,445
S6	(MH "Antineoplastic Agents+")		271,636
S5	S1 OR S2 OR S3 OR S4		33,511
S4	((hydatidiform or invasive) and mole*)		24,697
S3	(GTT or GTD or GTN)		3,386
S2	("gestational trophoblastic" N2 (neoplasm* or tumor* or tumour* or disease*))		1,830
S1	(MH "Gestational Trophoblastic		10,239

Other/Secondary Resources Searched

UpToDate, Cochrane

Search Strategy: Other Resources

Comments

Date